Media / Science Center

Media/
Science Center

Videos

See the latest “Ask Me Anything” interview with our CEO, Lynn Kirkpatrick

Pain Week 2025 Symposium

Pain Management – RE- invited.

Dr J Gudin discusses why opioids are critical

Dr J Gudin explains about PF614

Dr J Gudin discusses PF614-MPAR

Dr T Bertoch the next generation of analgesics

Dr William Schmidt discusses how PF614 TAAP works – from the IASP World Congress 2024.

Dr William Schmidt discusses the ideal analgesic profile – from the IASP World Congress 2024.

Dr J Gudin discusses the ideal analgesic

Dr. Dart introducing MPAR overdose protection

Pain Week 2023

Ensysce Biosciences CEO Lynn Kirkpatrick discusses the opioid crisis and next generation opioids

Podcasts

22:34

Drug Discovery World – Dr Lynn Kirkpatrick explains PF614-MPAR

Drug Discovery World – Dr Lynn Kirkpatrick explains PF614-MPAR Download Transcript

12:12

Stock Day Podcast – Dr. Lynn Kirkpatrick talks about TAAP, MPAR and pain relief products

Stock Day Podcast – Dr. Lynn Kirkpatrick talks about TAAP, MPAR and pain relief products Download Transcript

Abstracts & Manuscripts

Sept, 2025

Morphine Withdrawal Infographic

Download PDF

March 2024

Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.

Download PDF

February 2024

A Novel Trypsin Activated Abuse Protected (TAAP™) ER Oxycodone Prodrug with Overdose Protection

Download PDF

March 2024

Preventing Prescription Drug Overdoses, Clinical development of Trypsin-Activated Abuse Deterrent (TAAP) Opioids with Overdose Protection

Download PDF

October 2023

Development of an extended release nafamostat formulation for prescription drug overdose protection.

Download PDF

September 2023

PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection. In: Symposium on Severe Pain, Next Generation Solutions – PF614 / PF614-MPAR.

Download PDF

September 2023

PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection.

Download PDF

September 2023

Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Oxycodone Prodrug.

Download PDF

September 2023

Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug.

Download PDF

July 2023

Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose.

Download PDF

June 2023

Intranasal Human Abuse Potential of PF614: A Novel ‘Next Generation’ Trypsin Activated Abuse Protected (TAAP) Opioid.

Download PDF

February 2023

MPAR: A Chemical Approach to Opioid Overdose Protection.

Download PDF

May 2022

The Next Generation Opioid Products for Moderate-Severe Pain